Amgen's Uplizna Shows Promise in Myasthenia Gravis Trial, Rocatinlimab Data Disappoints

Amgen查看公司主页's recent Phase 3 trial results for Uplizna查看药品详情 in generalized myasthenia gravis (搜索)搜索该疾病 (gMG) have shown clinically meaningful and statistically significant efficacy, while data for rocatinlimab查看药品详情 in atopic dermatitis (搜索)搜索该疾病 has been met with skepticism by Wall Street analysts. The MINT trial results for Uplizna were presented at the American Association of Neuromuscular & Electrodiagnostic Medicine (AANEM) Annual Meeting.

Uplizna's Positive Results in gMG

The Phase 3 MINT trial evaluated Uplizna查看药品详情 (inebilizumab-cdon) in adults with gMG, a rare autoimmune disorder. The trial met its primary endpoint, demonstrating a statistically significant change from baseline in Myasthenia Gravis (搜索)搜索该疾病 Activities of Daily Living (MG-ADL) score for Uplizna (-4.2) compared with placebo (-2.2) (difference: –1.9, p<0.0001) at Week 26 for the combined study population. The study included patients who are acetylcholine receptor autoantibody-positive (AChR+) and those who are muscle-specific kinase autoantibody-positive (MuSK+).

Uplizna查看药品详情 also demonstrated statistically significant and clinically meaningful changes from baseline compared to placebo for the first four key secondary endpoints:

• Significant change in Quantitative Myasthenia Gravis (QMG) score for the combined population (-4.8) compared to placebo (-2.3) at Week 26 (difference: -2.5, p=0.0002).
• In the AChR+ population, Uplizna demonstrated mean change from baseline (-4.2) in MG-ADL score at Week 26 compared to placebo (-2.4) (difference: -1.8, p=0.0015).
• In the AChR+ population, Uplizna demonstrated mean change from baseline (-4.4) in QMG score at Week 26 compared to placebo (-2.0) (difference -2.5, p=0.0011).
• In the MuSK+ population, Uplizna demonstrated mean change from baseline (-3.9) in MG-ADL score at Week 26 compared to placebo (-1.7) (difference -2.2, p=0.0297).

Notably, patients taking corticosteroids at the start of the study were tapered down to prednisone 5 mg per day by Week 24. No new safety signals were identified.

Richard J. Nowak, M.D., M.S., global principal study investigator and director of the Myasthenia Gravis (搜索)搜索该疾病 Clinic at Yale University, emphasized the clinical benefits of Uplizna查看药品详情, noting that the trial also included a protocol-specified steroid taper, which is an important consideration for patients given the adverse effects of prolonged high-dose steroid use.

Amgen查看公司主页 plans to file for approval of Uplizna查看药品详情 in the U.S., followed by other key markets, based on the MINT trial results.

Rocatinlimab's Atopic Dermatitis Data Under Scrutiny

While Amgen查看公司主页 is expanding the treatment options, its rocatinlimab查看药品详情, designed to treat atopic dermatitis (搜索)搜索该疾病, showed statistically significant improvement versus placebo. However, analysts have expressed concerns about its efficacy profile, especially when there are still questions about safety.

Nearly 33% of patients in the study witnessed a significant improvement in their eczema symptoms. Amgen查看公司主页 is also studying the medicine in asthma and prurigo nodularis.

Analysts suggest the drug needed to show an especially high efficacy profile to counter safety concerns. The results are underwhelming, especially when compared to Sanofi查看公司主页 and Regeneron Pharmaceuticals查看公司主页’ Dupixent查看药品详情.